Axogen, Inc. has announced its third-quarter financial results for 2026, showcasing a significant increase in revenue and a positive outlook for the remainder of the year. The company reported a revenue of $75.8 million, marking a 26.2% increase from the same quarter last year. This growth has prompted Axogen to raise its full-year revenue guidance to at least $290 million, reflecting a projected growth rate of 29%.

Michael Dale, President and CEO of Axogen, expressed satisfaction with the company's performance, stating, "We are delighted with our third-quarter and year-to-date revenue performance and the progress we continue to make across each of Axogen’s strategic plan priorities. Our strong growth across all markets continues to validate our market development strategies and the strength of our commercial execution."

Background

Axogen, Inc., incorporated in Minnesota, operates in the electromedical and electrotherapeutic apparatus sector (SIC 3845). The company is listed on the Nasdaq under the ticker symbol AXGN. It specializes in developing and marketing innovative surgical solutions aimed at restoring peripheral nerve function. Axogen has been active in the market, with its recent filings indicating a focus on growth and expansion.

What the Filing Says

The recent SEC filing, dated October 28, 2026, highlights Axogen's third-quarter financial results. The company reported a gross margin of 74.8%, and net income of $2.3 million, or $0.04 per share, compared to $0.7 million, or $0.01 per share, for the same period last year. Adjusted net income was $13.1 million, or $0.21 per share, up from $6.1 million, or $0.12 per share, in Q3 2025.

Impact

Axogen's strong performance may influence its competitors in the electromedical industry, as the company continues to capture market share and expand its product offerings. The positive financial results and raised guidance may pressure other companies in the sector to enhance their strategies and offerings to maintain competitiveness.

What's Next

Details were not available in the SEC filing regarding specific next steps for Axogen following this announcement. However, the company is expected to continue leveraging its recent successes to drive future growth.